We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Flow Cytometry Assay Measures NK Cell Function

By LabMedica International staff writers
Posted on 13 May 2013
Peripheral blood natural killer (NK) cell function in healthy adults has been assessed using the target-induced NK loss (TINKL) assay.

The TINKL assay is a sensitive flow cytometry-based assay for measuring NK cell function; its clinical application has been evaluated and the activity measured, which is independent of the number of NK cells in the assay. More...


Immunologists at The Canberra Hospital (Garran, ACT, Australia) collected blood from 70 healthy adult male, and 53 healthy female volunteers. Their mean age (± standard deviation) was 38 ± 11 years, ranging from 19 to 65 years. Venous blood was collected in vacutainers containing ethylenediaminetetraacetic acid (EDTA), and samples were processed within 24 hours. Peripheral blood mononuclear cells (PBMC) were isolated, cryopreserved, and stored in liquid nitrogen. On the day prior to assay, PBMC were thawed and maintained in culture overnight.

The TINKL assay was conducted using NK-sensitive erythroleukaemic cell K562 was used to measure natural killing, and the NK-resistant Raji B lymphoblastoid cell in the presence of the CD20 monoclonal antibody Rituximab was used to measure antibody-dependent killing. Peripheral blood NK cell function measured by the TINKL assay was assessed in repeated samples of 123 healthy adults.

The PBMC were assayed in 21 trials over a three-month period. NK loss was 31% ± 10% (range 7% to 55%) as a consequence of natural killing, and 39% ± 10% (range 14% to 64%) as a consequence of antibody-dependent killing. The variation in NK cell function in the population measured by the TINKL assay is greater than can be accounted for by interexperimental variability. The intraexperimental coefficient of variation (CV) was on average 11% for natural killing and 3% for antibody-dependent killing, compared to 14% and 9% respectively for the interexperimental variation.

The authors concluded that their data provides additional information on the TINKL assay relevant to testing NK cell function in a clinical setting. The intra-experimental variability and the inter-experimental variability of the assay have been quantified, and the large range in NK cell function in a population of healthy donors is now chronicled. The study was published on April 6, 2013, in the Journal of Immunological Methods.

Related Links:
The Canberra Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination

Reliable confirmation of mpox can be difficult where multiple rash-causing illnesses co-circulate and laboratory capacity is limited. Although PCR is central to case detection, contamination during specimen... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.